Profil bibliographique

Heidi Giordano

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

89Publications signalées

5897Citations signalées

1Affiliations récentes

Les institutions déclarées

Clovis Oncology (United States)

Les domaines associés

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentCancer Genomics and DiagnosticsCRISPR and Genetic EngineeringBRCA gene mutations in cancer

Les publications récentes

2024 conference-abstract OpenAlex

Abstract C006: LODESTAR: A Single Arm Phase II Study of Rucaparib in Solid Tumors with Pathogenic Germline or Somatic Variants in Homologous Recombination Repair (HRR) Genes

Sriram Anbil, Nicholas J. Seewald, Kevin Lin, Marcia Craib et autres

us (code pays fourni par la source)

0 citations Cancer Research

Accès ouvert 2023 other OpenAlex

Table S2 from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin et autres

0 citations

Accès ouvert 2023 other OpenAlex

Table S3 from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin et autres

1 citation

Accès ouvert 2023 other OpenAlex

Data from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin et autres

0 citations

Accès ouvert 2023 other OpenAlex

Figures S1-S8 from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin et autres

0 citations

Accès ouvert 2023 other OpenAlex

Table S1 from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin et autres

0 citations

Accès ouvert 2023 other OpenAlex

Data from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin et autres

0 citations

Accès ouvert 2023 other OpenAlex

Figures S1-S8 from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin et autres

0 citations

Accès ouvert 2023 other OpenAlex

Table S1 from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin et autres

0 citations

Accès ouvert 2023 other OpenAlex

Table S3 from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin et autres

0 citations

Accès ouvert 2023 other OpenAlex

Table S2 from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin et autres

0 citations

Accès ouvert 2023 other OpenAlex

Supp Table 1 from Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Olga Kondrashova, Minh Tho Nguyen, Kristy Shield‐Artin, Anna V. Tinker et autres

0 citations

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.